Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 3-18 , March 2008

Achondroplasia

References 

  1. Maroteaux P, Le Merrer M. L'achondroplasie. In: Maladies Osseuses de l'Enfant. Fammarion Medecine Science. 4th edn. Paris, 2002, pp. 56–65.
  2. Oberklaid F, Danks DM, Jensen F, et al. Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. Journal of Medical Genetics. 1979;16:140–146
  3. Orioli IM, Castila EE, Scarano G, Mastroiacovo P. Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. American Journal of Medical Genetics. 1995;59:209–217
  4. Stoll C, Dott B, Roth MP, Alembik Y. Birth prevalence rates of skeletal dysplasias. Clinical Genetics. 1989;35:88–92
  5. Martinez-Frias ML, Cereijo A, Bermejo E, et al. Epidemiological aspects of Mendelian syndromes in a Spanish population sample: II. Autosomal dominant malformation syndromes. American Journal of Medical Genetics. 1991;38:622–625
  6. Dakouane Giudicelli M, Serazin V, Le Sciellour CR, et al. Increased achondroplasia mutation frequency with advanced age and evidence for G1138A mosaicism in human testis biopsies. Fertility and Sterility. 2007;11:
  7. Cordone M, Lituania M, Bocchino G, et al. Ultrasonographic features in a case of heterozygous achondroplasia at 25 weeks' gestation. Prenatal Diagnosis. 1993;13:395–401
  8. Mesoraca A, Pilu G, Perolo A, et al. Ultrasound and molecular mid-trimester prenatal diagnosis of de novo achondroplasia. Prenatal Diagnosis. 1996;16:764–768
  9. Krakow D, Williams J, Poehl M, et al. Use of three-dimensional ultrasound imaging in the diagnosis of prenatal-onset skeletal dysplasias. Ultrasound in Obstetrics & Gynecology. 2003;21:467–472
  10. Ruano R, Molho M, Roume J, Ville Y. Prenatal diagnosis of fetal skeletal dysplasias by combining two-dimensional and three-dimensional ultrasound and intrauterine three-dimensional helical computer tomography. Ultrasound in Obstetrics & Gynecology. 2004;24:134–140
  11. Trotter TL, Hall JG. American Academy of Pediatrics Committee on Genetics. Health supervision for children with achondroplasia. Pediatrics. 2005;116:771–783
  12. Horton WA, Rotter JI, Rimoin DL, et al. Standard growth curves for achondroplasia. The Journal of Pediatrics. 1978;93:435–438
  13. Taybi H, Lachman R. Achondroplasia. In: Radiology of syndromes, metabolic disorders and skeletal dysplasias. 4th edn.. St Louis: CV Mosby; 2000;p. 749–755
  14. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370:162–172
  15. Hunter AGW, Bankier A, Rogers JG, et al. Medical complications of achondroplasia: a multicentre patient review. Journal of Medical Genetics. 1998;35:705–712
  16. Carter EM, Davis JG, Raggio CL. Advances in understanding etiology of achondroplasia and review of management. Current Opinion in Pediatrics. 2007;19:32–37
  17. Bruhl K, Stoeter P, Wietek B, et al. Cerebral spinal fluid flow, venous drainage and spinal cord compression in achondroplastic children: impact of magnetic resonance findings for decompressive surgery at the cranio-cervical junction. European Journal of Pediatrics. 2001;160:10–20
  18. Hecht JT, Horton WA, Reid CS, et al. Growth of the foramen magnum in achondroplasia. American Journal of Medical Genetics. 1989;32:528–535
  19. Pierre-Kahn A, Hirsch JF, Renier D, et al. Hydrocephalus and achondroplasia. A study of 25 observations. Child's Brain. 1980;7:205–219
  20. Reid CS, Pyeritz RE, Kopits SE, et al. Cervicomedullary compression in young patients with achondroplasia: value of comprehensive neurologic and respiratory evaluation. The Journal of Pediatrics. 1987;110:522–530
  21. Ryken TC, Menezes AH. Cervicomedullary compression in achondroplasia. Journal of Neurosurgery. 1994;81:43–48
  22. Bagley CA, Pindrik JA, Bookland MJ, et al. Cervicomedullary decompression for foramen magnum stenosis in achondroplasia. Journal of Neurosurgery. 2006;104:166–172
  23. Rimoin DL. Cervicomedullary junction compression in infants with achondroplasia: when to perform neurosurgical decompression. American Journal of Human Genetics. 1995;56:824–827
  24. Ho NC, Guarnieri M, Brant LJ. Living with achondroplasia: quality of life evaluation following cervico-medullary decompression. American Journal of Medical Genetics. Part A. 2004;131:163–167
  25. Boor R, Fricke G, Brühl K, Spranger J. Abnormal subcortical somatosensory evoked potentials indicate high cervical myelopathy in achondroplasia. European Journal of Pediatrics. 1999;158:662–667
  26. Sciubba DM, Noggle JC, Marupudi NI, et al. Spinal stenosis surgery in pediatric patients with achondroplasia. Journal of Neurosurgery. 2007;106:372–378
  27. Pauli RM, Breed A, Horton VK, et al. Prevention of fixed, angular kyphosis in achondroplasia. Journal of Pediatric Orthopedics. 1997;7:726–733
  28. Kopits SE. Correction of bowleg deformity in achondroplasia. The Johns Hopkins Medical Journal. 1980;146:206–209
  29. Pauli RM, Scott CI, Wassman ER, et al. Apnea and sudden unexpected death in infants with achondroplasia. The Journal of Pediatrics. 1984;104:342–348
  30. Hecht JT, Francomano CA, Horton WA, Annegers JF. Mortality in achondroplasia. American Journal of Human Genetics. 1987;41:454–464
  31. Waters KA, Everett F, Sillence DO, et al. Treatment of obstructive sleep apnea in achondroplasia: evaluation of sleep, breathing, and somatosensory-evoked potentials. American Journal of Medical Genetics. 1995;59:460–466
  32. Tasker RC, Dundas I, Laverty A, et al. Distinct patterns of respiratory difficulty in young children with achondroplasia: a clinical, sleep, and lung function study. Archives of Disease in Childhood. 1998;79:99–108
  33. Hecht JT, Hood OJ, Schwartz RJ, et al. Obesity in achondroplasia. American Journal of Medical Genetics. 1988;31:597–602
  34. Wynn J, King TM, Gambello MJ, et al. Mortality in achondroplasia study: a year follow-up. American Journal of Medical Genetics. Part A. 2007;143:2502–2511
  35. Gardner RJM. A new estimate of the achondroplasia mutation rate. Clinical Genetics. 1977;11:31–38
  36. Le Merrer M, Rousseau F, Legeai-Mallet L, et al. A gene for achondroplasia-hypochondroplasia maps to chromosome 4p. Nature Genetics. 1994;6:318–321
  37. Velinov M, Slaugenhaupt SA, Stoilov I, et al. The gene for achondroplasia maps to the telomeric region of chromosome 4p. Nature Genetics. 1994;6:314–317
  38. Rousseau F, Bonaventure J, Legeai-Mallet L. Clinical and genetic heterogeneity of hypochondroplasia. Journal of Medical Genetics. 1996;33:749–752
  39. Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78:335–342
  40. Bellus GA, Hefferon TW, Ortiz de Luna RI, et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. American Journal of Human Genetics. 1995;56:368–373
  41. Opitz JM. Editorial comment: unstable premutation in achondroplasia: penetrance vs phenotrance. American Journal of Medical Genetics. 1984;19:251–254
  42. Philip N, Auger M, Mattei JF, Giraud F. Achondroplasia in sibs of normal parents. Journal of Medical Genetics. 1988;5:857–859
  43. Fryns JP, Kleczkowska A, Verresen H, van den Berghe H. Germinal mosaicism in achondroplasia: a family with 3 affected siblings of normal parents. Clinical Genetics. 1983;24:156–158
  44. Mettler G, Fraser FC. Recurrence risk for sibs of children with ‘sporadic’ achondroplasia. American Journal of Medical Genetics. 2000;90:250–251
  45. Murdoch JL, Walker BA, Hall JG, et al. Achondroplasia, a genetic and statistical survey. Annals of Human Genetics. 1970;33:227–244
  46. Wilkin DJ, Szabo JK, Cameron R, et al. Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome. American Journal of Medical Genetics. 1998;63:711–716
  47. Goriely A, McVean GA, van Pelt AM, et al. Gain-of-function amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:6051–6056
  48. Bellus GA, McIntosch I, Smith AE, et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nature Genetics. 1995;10:357–359
  49. Grigelioniene G, Eklof O, Laurencikas E, et al. L.Asn540Lys mutation in fibroblast growth factor receptor 3 and phenotype in hypochondroplasia. Acta Paediatrica. 2000;89:1072–1076
  50. Bellus GA, Spector EB, Speiser PW, et al. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. American Journal of Human Genetics. 2000;67:1411–1421
  51. Winterpacht A, Hilbert K, Stelzer C, et al. A novel mutation in FGFR-3 disrupts a putative N-glycosylation site and results in hypochondroplasia. Physiological Genomics. 2000;2:9–12
  52. Stoilov I, Kilpatrick MW, Tsipouras P. A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia. American Journal of Human Genetics. 1995;55:127–133
  53. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocrine Reviews. 2000;21:23–39
  54. Rousseau F, Bonaventure J, Le Merrer M, et al. Mutations of FGFR3 gene cause 3 types of nanisms with variably severity: achondroplasia, thanatophoric nanism and hypochondroplasia. Annales d'endocrinologie (Paris). 1996;57:153
  55. Tavormina PL, Bellus GA, Webster MK. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. American Journal of Human Genetics. 1999;64:722–731
  56. Muenke M, Gripp KW, McDonald-McGinn DM, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. American Journal of Human Genetics. 1997;60:555–564
  57. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–225
  58. Pejchalova K, Krejci P, Wilcox WR. C-natriuretic peptide: an important regulator of cartilage. Molecular Genetics and Metabolism 2007;92: 210–215.
  59. Gibbs L, Legeai-Mallet L. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. Biochimica Et Biophysica Acta. 2007;1773(4):502–512
  60. Hafner C, van Oers JM, Tb Vogt, et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. The Journal of Clinical Investigation. 2006;116:2201–2207
  61. Gollust SE, Thompson RE, Gooding HC, Biesecker BB. Living with achondroplasia: attitudes toward population screening and correlation with quality of life. Prenatal Diagnosis. 2003;23:1003–1008
  62. Horton WA, Hecht JT, Hood OJ, et al. Growth hormone therapy in achondroplasia. American Journal of Medical Genetics. 1992;42:667–670
  63. Shohat M, Tick D, Barakat S, et al. Short-term recombinant human growth hormone treatment increases growth rate in achondroplasia. Journal of Clinical Endocrinology & Metabolism. 1996;81:4033–4037
  64. Seino Y, Yamanaka Y, Shinohanora M, et al. Growth hormone therapy in achondroplasia. Hormone Research. 2000;533:53–56
  65. Aldegheri R, Trivella G, Renzi-Brivio L, et al. Lengthening of the lower limbs in achondroplastic patients. A comparative study of four techniques. The Journal of Bone and Joint Surgery. 1988;70B:69–73
  66. Lavini F, Renzi-Brivio L, de Bastiani G. Psychologic, vascular, and physiologic aspects of lower limb lengthening inachondroplastics. Clinical Orthopaedics and Related Research. 1990;250:138–142
  67. Ganel A, Horoszowski H, Kamhin M, Farine I. Leg lengthening in achondroplastic children. Clinical Orthopaedics 1979; 144: 194–197.
  68. Ganel A, Horoszowski H. Limb lengthening in children with achondroplasia. Differences based on gender. Clinical Orthopaedics and Related Research. 1996;332:179–183
  69. Rauchenberger R, Borges E, Thomassen-Wolf E, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. The Journal of Biological Chemistry. 2003;278:194–205
  70. Yasoda A, Komatsu Y, Chusho H, et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Natural Medicines. 2004;101:80–86
  71. Benoist-Lasselin C, Gibbs L, Heuertz S, Odent T, Munnich A, Legeai-Mallet L. Human immortalized chondrocytes carrying heterozygous FGFR3 mutations: an in vitro model to study chondrodysplasias. FEBS Letters. 2007;581:2593–2598

PII: S1521-6942(07)00141-6

doi: 10.1016/j.berh.2007.12.008

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 3-18 , March 2008

Article Tools

* Image Usage & Resolution